Reality Check on Non-Small Cell Lung Cancer Systemic Therapy
Market access for Non-small cell lung cancer systemic therapy treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 46% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: When the FDA approved Novartis Pharmaceuticals Corp.’s Tabrecta (capmatinib) on May 6, 2020, it was the first of seven approvals in non-small cell lung cancer (NSCLC) through May 29
- Key Findings: Many systemic therapies to treat NSCLC are on the market today, and more than 10 are in Phase III trials. The discovery of genetic alterations that drive tumor growth has changed the clinical management of the disease and produced specific targeted therapies to treat the various genetic mutations
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.